An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 11, 2019

Primary Completion Date

December 20, 2021

Study Completion Date

October 26, 2022

Conditions
Gastric CancerGastroEsophageal Cancer
Interventions
DRUG

Bavituximab

Bavituximab IV infusion

DRUG

Pembrolizumab Injection

Pembrolizumab IV Infusion

Trial Locations (21)

704

National Cheng Kung University Hospital, Tainan City

10601

White Plains Hospital - Center for Cancer Care, White Plains

11217

Taipei Veterans General Hospital, Taipei

13620

Seoul National University Bundang Hospital, Seongnam-si

19124

Cancer Treatment Centers of America at Eastern Regional Medical Center, Philadelphia

31904

Columbus Regional Research Institute, Columbus

33305

Chang Gung Medical Foundation - Linkou Branch, Taoyuan District

33331

Cleveland Clinic Florida - Weston, Weston

37203

Sara Cannon Research Institute, Nashville

40447

China Medical University Hospital, Taichung

45229

UC Health Office of Clinical Research, Cincinnati

49201

Dong-A University Hospital, Busan

60637

The University of Chicago Medical Center, Chicago

63110

Siteman Cancer Center - Washington University Medical Campus, St Louis

06511

Smilow Cancer Hospital at Yale-New Haven, New Haven

702-210

Kyungpook National University Chilgok Hospital, Daegu

05505

Asan Medical Center, Seoul

06351

Samsung Medical Center, Seoul

110-744

Seoul National University Hospital, Seoul

SW3 6JJ

The Royal Marsden, London

W1G 6AD

Sarah Cannon Research Institute, London

Sponsors
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

OncXerna Theraputics, Inc.

INDUSTRY